News

Klotho shares have soared more than 1000% over the past three months on promising results and breakthrough hopes.
Klotho Neurosciences ( ($KLTO) ) has provided an announcement. On July 10, 2025, Klotho Neurosciences announced that the FDA granted Orphan Drug ...
Investing.com -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) stock surged 22% after the company announced that the U.S. Food and ...
Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...
Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation ...
US FDA grants orphan drug designation to Klotho Neurosciences’ KLTO-202 to treat amyotrophic lateral sclerosis: New York Saturday, July 12, 2025, 15:00 Hrs [IST] Klotho Neurosci ...
Shares of the anti-aging biogenetics company Klotho Neurosciences are on retail investors' radars after the stock exploded ...
Klotho Neurosciences’ competitors have higher revenue, but lower earnings than Klotho Neurosciences. Klotho Neurosciences is trading at a lower price-to-earnings ratio than its competitors ...
NEW YORK, July 10, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases ...
The U.S. FDA has granted orphan drug designation to Klotho Neurosciences Inc.’s secreted-Klotho (s-KL) promoter, gene and ...